Indaptus extends outside date for $24 million private placement to October 16

Indaptus Therapeutics filed a Form 8-K dated September 30, 2026 that reports an event occurring on September 29, 2026. Indaptus disclosed that on September 8, 2026 it had entered into a Stock Purchase Agreement with a group of purchasers to sell shares of common stock in a private placement for aggregate gross proceeds of approximately $24.0 million, before offering expenses.¹

Under that agreement, the closing was originally required to occur no later than September 29, 2026, referred to as the Outside Date.¹ On September 29, 2026, the company and the purchasers signed notices and consents extending the Outside Date for each purchaser to October 16, 2026, called the Extended Outside Date.¹

The notices and consents also let the company defer and coordinate closing with individual purchasers until their closing conditions are satisfied or waived, as long as that happens no later than the Extended Outside Date, unless the company and a given purchaser agree otherwise in writing.¹ The deadline for purchasers to fund their purchase prices, along with certain related termination rights, was also pushed to the Extended Outside Date.¹

Aside from these changes, the original Purchase Agreement remains unchanged and in full force and effect.¹ The extension notice was filed as an exhibit to the September 30, 2026 8-K, which was signed by Chief Executive Officer Junyi Dai.